AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11033398 — intervention group
Group type: COMPARATOR
Intervention: Control group (BCVA worse than 20/40)
Number of subjects: 50
Study 9314450 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin/clofazimine (Clm/Clof)
Number of subjects: 144
Study 9314450 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin/rifabutin/ethambutol (Clm/Rib/Eth)
Number of subjects: 144
Study 9314450 — intervention group
Group type: COMPARATOR
Intervention: Both treatment groups
Number of subjects: 144
Study 8400255 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) for 70 days
Number of subjects: 88
Study 8400255 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX)
Number of subjects: 88
Study 8400255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 3518625 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (1 g)
Number of subjects: 94
Study 3518625 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin (4 g)
Number of subjects: 94
Study 3518625 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 94
Study 28805066 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy with ACM device
Number of subjects: 50
Study 27136096 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate (VPA) 1500mg/day
Number of subjects: 28
Study 27136096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 27136096 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate (VPA)
Number of subjects: 28
Study 24396842 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-Lok type implants (n = 39)
Number of subjects: 77
Study 24396842 — intervention group
Group type: COMPARATOR
Intervention: Non-Laser-Lok type implants (n = 39)
Number of subjects: 77
Study 24396842 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 77
Study 22081867 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP) containing ART regimen
Number of subjects: 46
Study 20203244 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal fluticasone propionate, 200 microg twice a day for 3 days after 14 days of oxymetazoline
Number of subjects: 19
Study 20203244 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxymetazoline, 200 microg three times a day for 14 days
Number of subjects: 19
Study 20203244 — intervention group
Group type: COMPARATOR
Intervention: Oral prazosin, 1 mg
Number of subjects: 19
Study 17653243 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin inhibition (ACE inhibitor or angiotensin receptor blocker)
Number of subjects: 102
Study 17653243 — intervention group
Group type: COMPARATOR
Intervention: No angiotensin inhibition (Control)
Number of subjects: 102
Study 15799687 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg twice weekly
Number of subjects: 0
Study 15799687 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg twice weekly, alone or in combination with methotrexate
Number of subjects: 0
Study 15799687 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg twice weekly
Number of subjects: 0
Study 12553620 — intervention group
Group type: EXPERIMENTAL
Intervention: Optibond FL
Number of subjects: 70
Study 12553620 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluma One Bond
Number of subjects: 70
Study 12553620 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond
Number of subjects: 70
Study 12553620 — intervention group
Group type: EXPERIMENTAL
Intervention: Acid etching plus Clearfil SE Bond
Number of subjects: 70
Study 12553620 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompt‐L‐Pop
Number of subjects: 70
Study 10076315 — intervention group
Group type: EXPERIMENTAL
Intervention: Known midwife during antenatal care
Number of subjects: 410
Study 10076315 — intervention group
Group type: EXPERIMENTAL
Intervention: Known midwife during intrapartum care
Number of subjects: 410
Study 10076315 — intervention group
Group type: EXPERIMENTAL
Intervention: Known midwife during postpartum domiciliary care
Number of subjects: 410
Study 7776222 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonskid socks
Number of subjects: 0
Study 2096746 — intervention group
Group type: EXPERIMENTAL
Intervention: Articaine HCl (Ultracaine DS)
Number of subjects: 0
Study 2096746 — intervention group
Group type: COMPARATOR
Intervention: Prilocaine HCl (Citanest Forte)
Number of subjects: 0
Study 369515 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg ethynodiol diacetate + 0.1 mg mestranol ('Ovulen')
Number of subjects: 20
Study 369515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31372679 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet group (n=50)
Number of subjects: 99
Study 31372679 — intervention group
Group type: COMPARATOR
Intervention: Non-tourniquet group (n=49)
Number of subjects: 99
Study 29189955 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra‐ and peri‐articular blood injection (Group A)
Number of subjects: 40
Study 29189955 — intervention group
Group type: COMPARATOR
Intervention: Peri‐articular injection alone (Group B)
Number of subjects: 40
Study 27270706 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 20-s Wingate sprint, 3 sessions per week for 4 weeks
Number of subjects: 30
Study 24828894 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (perindopril ± indapamide)
Number of subjects: 6105
Study 24828894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6105
Study 23024308 — intervention group
Group type: EXPERIMENTAL
Intervention: Light periodontal curettes (14 grams, 11 millimeters diameter)
Number of subjects: 110
Study 23024308 — intervention group
Group type: COMPARATOR
Intervention: Heavy periodontal curettes (34 grams, 8 millimeters diameter)
Number of subjects: 110
Study 20979909 — intervention group
Group type: COMPARATOR
Intervention: CTrach group (C)
Number of subjects: 60
Study 20979909 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngoscope group (D)
Number of subjects: 60
Study 18823470 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl 50 microg
Number of subjects: 103
Study 18823470 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl 75 microg
Number of subjects: 103
Study 18823470 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl 100 microg
Number of subjects: 103
Study 16060416 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based physical activity intervention (n=27)
Number of subjects: 36
Study 16060416 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=9)
Number of subjects: 36
Study 11840080 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV gB/MF59 vaccine (20 microg)
Number of subjects: 18
Study 11840080 — intervention group
Group type: COMPARATOR
Intervention: Control hepatitis A vaccine
Number of subjects: 18
Study 10554936 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate induction of labour with oxytocin (Group 1)
Number of subjects: 126
Study 10554936 — intervention group
Group type: COMPARATOR
Intervention: Expectant management (Group 2)
Number of subjects: 126
Study 10554936 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectant management with spontaneous labour (Group 2B)
Number of subjects: 126
Study 10554936 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectant management with induced labour after 24 hours (Group 2A)
Number of subjects: 126
Study 8907724 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily enteric-coated sodium valproate tablets
Number of subjects: 18
Study 8907724 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily controlled release tablets (Epilim Chrono)
Number of subjects: 18
Study 8907724 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily controlled release tablets (Epilim Chrono)
Number of subjects: 18
Study 8907724 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 18
Study 1906610 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 400 micrograms twice daily
Number of subjects: 12
Study 1906610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6866591 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride (Ritalin) given with breakfast
Number of subjects: 11
Study 6866591 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride (Ritalin) given 30 minutes before breakfast
Number of subjects: 11
Study 6866591 — intervention group
Group type: COMPARATOR
Intervention: Placebo control condition
Number of subjects: 11
Study 30360014 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg under fasted conditions
Number of subjects: 0
Study 30360014 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg under fed conditions
Number of subjects: 0
Study 30360014 — intervention group
Group type: COMPARATOR
Intervention: High-fat food effect on etoricoxib
Number of subjects: 0
Study 28566209 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose TKI therapy (imatinib 200 mg daily, dasatinib 50 mg daily, or nilotinib 200 mg twice daily) for 12 months
Number of subjects: 174
Study 26475066 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiation therapy
Number of subjects: 171
Study 26475066 — intervention group
Group type: COMPARATOR
Intervention: Early salvage radiation therapy
Number of subjects: 171
Study 26475066 — intervention group
Group type: EXPERIMENTAL
Intervention: IMRT
Number of subjects: 171
Study 26475066 — intervention group
Group type: COMPARATOR
Intervention: 3-dimensional conformal radiation therapy
Number of subjects: 171
Study 26475066 — intervention group
Group type: EXPERIMENTAL
Intervention: Each additional patient accrued
Number of subjects: 171
Study 26475066 — intervention group
Group type: EXPERIMENTAL
Intervention: First 5 patients accrued
Number of subjects: 171
Study 24065371 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention centers
Number of subjects: 32
Study 24065371 — intervention group
Group type: COMPARATOR
Intervention: Control centers
Number of subjects: 32
Study 22055834 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational intervention (PMT)
Number of subjects: 84
Study 22055834 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined motivational and volitional intervention (PMT&APCP)
Number of subjects: 84
Study 22055834 — intervention group
Group type: EXPERIMENTAL
Intervention: Volitional intervention (APCP)
Number of subjects: 84
Study 22055834 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 84
Study 19847160 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg citalopram
Number of subjects: 16
Study 19847160 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg reboxetine
Number of subjects: 16
Study 19847160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 17556106 — intervention group
Group type: EXPERIMENTAL
Intervention: Bereavement intervention program (Dan-jeon breathing sessions, self-help group activity, health check)
Number of subjects: 0
Study 17556106 — intervention group
Group type: COMPARATOR
Intervention: Control group (only health check)
Number of subjects: 0
Study 16246947 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg daily)
Number of subjects: 50
Study 16246947 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 50
Study 11826352 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular pacing (BP)
Number of subjects: 24
Study 10422927 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml/kg intravenous fluid
Number of subjects: 324
Study 10422927 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ml/kg intravenous fluid
Number of subjects: 324
Study 10422927 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk patients (category 3 and 4)
Number of subjects: 324
Study 10422927 — intervention group
Group type: COMPARATOR
Intervention: Low-risk patients (category 1)
Number of subjects: 324
Study 10422927 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring bladder volumes by ultrasound
Number of subjects: 324
Study 8665556 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine 1.5 mg
Number of subjects: 0
Study 8665556 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine 3 mg
Number of subjects: 0
Study 8665556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1688044 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxatomide gel at 5%
Number of subjects: 27
Study 1688044 — intervention group
Group type: COMPARATOR
Intervention: Dechlorpheniramine cream at 1%
Number of subjects: 27
Study 6642380 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg orally in the evening and 400 mg intramuscularly two hours prior to induction of anesthesia
Number of subjects: 30
Study 6642380 — intervention group
Group type: COMPARATOR
Intervention: No specific medication (Control)
Number of subjects: 30
Study 31393399 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg subcutaneously every 6 months
Number of subjects: 0
Study 31393399 — intervention group
Group type: COMPARATOR
Intervention: Letrozole 2.5 mg or Anastrozole 1 mg once a day
Number of subjects: 0
Study 28441993 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 683
Study 28441993 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg
Number of subjects: 683
Study 28441993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 683
Study 27129610 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal alcohol exposure (PAE)
Number of subjects: 344
Study 27129610 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint exposure to PAE and prenatal depressive symptoms
Number of subjects: 344
Study 27129610 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal depressive symptoms
Number of subjects: 344
Study 27129610 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual dimorphism in joint exposures
Number of subjects: 344
Study 24714056 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention
Number of subjects: 133
Study 24714056 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training intervention
Number of subjects: 133
Study 19258966 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine (basal 8 mL/h, bolus 4 mL)
Number of subjects: 50
Study 19258966 — intervention group
Group type: COMPARATOR
Intervention: 0.4% ropivacaine (basal 4 mL/h, bolus 2 mL)
Number of subjects: 50
Study 19258966 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4% ropivacaine
Number of subjects: 50
Study 15100626 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle stimulation of active myofascial trigger points
Number of subjects: 21
Study 15100626 — intervention group
Group type: COMPARATOR
Intervention: Needle stimulation of latent myofascial trigger points
Number of subjects: 21
Study 11116103 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (5 mg)
Number of subjects: 38
Study 11116103 — intervention group
Group type: COMPARATOR
Intervention: Nitrendipine (10 mg)
Number of subjects: 38
Study 9123707 — intervention group
Group type: EXPERIMENTAL
Intervention: Orchiectomy plus estramustine phosphate (O + E)
Number of subjects: 419
Study 9123707 — intervention group
Group type: COMPARATOR
Intervention: Orchiectomy (O)
Number of subjects: 419
Study 8322135 — intervention group
Group type: EXPERIMENTAL
Intervention: Open vaginal vault method with preoperative cefonicid administration
Number of subjects: 137
Study 8322135 — intervention group
Group type: COMPARATOR
Intervention: Closed vaginal vault method (control group)
Number of subjects: 137
Study 3524970 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal (500 mg twice daily)
Number of subjects: 38
Study 3524970 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylbutazone (200 mg twice daily)
Number of subjects: 38
Study 3524970 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal
Number of subjects: 38
Study 3524970 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylbutazone
Number of subjects: 38
Study 3524970 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 38
Study 31869820 — intervention group
Group type: EXPERIMENTAL
Intervention: SAU (sauna bathing) - 3 × 8 min at 80‐85°C
Number of subjects: 20
Study 31869820 — intervention group
Group type: COMPARATOR
Intervention: PLAC (placebo condition - deidentified, pH‐balanced massage oil while passively resting)
Number of subjects: 20
Study 27863806 — intervention group
Group type: COMPARATOR
Intervention: ABT‐493 25-800 mg (single doses)
Number of subjects: 0
Study 27863806 — intervention group
Group type: COMPARATOR
Intervention: ABT‐493 200-800 mg (multiple doses)
Number of subjects: 0
Study 27863806 — intervention group
Group type: COMPARATOR
Intervention: ABT‐493 (all doses)
Number of subjects: 0
Study 27863806 — intervention group
Group type: COMPARATOR
Intervention: ABT‐493 with food
Number of subjects: 0
Study 27822448 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with endometrial cancer (EC)
Number of subjects: 88
Study 27822448 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients without gynecological pathology or inflammatory disorders)
Number of subjects: 88
Study 27822448 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal fat measurement
Number of subjects: 88
Study 24950985 — intervention group
Group type: EXPERIMENTAL
Intervention: Trebananib (15 mg/kg) plus weekly intravenous paclitaxel (80 mg/m²)
Number of subjects: 919
Study 24950985 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus weekly intravenous paclitaxel (80 mg/m²)
Number of subjects: 919
Study 24950985 — intervention group
Group type: EXPERIMENTAL
Intervention: Trebananib (15 mg/kg)
Number of subjects: 919
Study 24950985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 919
Study 22271764 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori treatment
Number of subjects: 3365
Study 22271764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3365
Study 22271764 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin treatment
Number of subjects: 3365
Study 22271764 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic treatment
Number of subjects: 3365
Study 19417716 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA (ecstasy) administration in humans
Number of subjects: 0
Study 19417716 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA (ecstasy) administration in squirrel monkeys
Number of subjects: 0
Study 19417716 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA (ecstasy) administration in both species
Number of subjects: 0
Study 17853767 — intervention group
Group type: EXPERIMENTAL
Intervention: Ear point blood‐letting combined with cupping at Back‐shu points
Number of subjects: 0
Study 17853767 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of Tetracycline and external application of Cuochuangping Ointment
Number of subjects: 0
Study 15172901 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct observation of competence workshop
Number of subjects: 40
Study 15172901 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 11182474 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg tiagabine
Number of subjects: 10
Study 11182474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 9164315 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide 135 micrograms/kg bolus followed by 0.5 microgram kg‐1 min‐1 infusion for 20‐24 h
Number of subjects: 4010
Study 9164315 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide 135 micrograms/kg bolus followed by 0.75 microgram kg‐1 min‐1 infusion for 20‐24 h
Number of subjects: 4010
Study 9164315 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4010
Study 9164315 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide treatment
Number of subjects: 4010
Study 8243223 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 2130
Study 8243223 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2130
Study 3667060 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 calorie protein‐sparing modified fast (PSMF)
Number of subjects: 28
Study 3667060 — intervention group
Group type: COMPARATOR
Intervention: 1200‐kcal balanced diet
Number of subjects: 28
Study 28676957 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesenteric defect closure
Number of subjects: 2507
Study 28676957 — intervention group
Group type: COMPARATOR
Intervention: Non-closure
Number of subjects: 2507
Study 27697447 — intervention group
Group type: COMPARATOR
Intervention: Medium adherence (MMAS‐8: 6 to <8)
Number of subjects: 8435
Study 27697447 — intervention group
Group type: COMPARATOR
Intervention: Low adherence (MMAS‐8: <6)
Number of subjects: 8435
Study 27697447 — intervention group
Group type: EXPERIMENTAL
Intervention: High adherence (MMAS‐8: 8)
Number of subjects: 8435
Study 24666767 — intervention group
Group type: EXPERIMENTAL
Intervention: IV clonidine 2 mcg·kg(‐1)
Number of subjects: 90
Study 24666767 — intervention group
Group type: EXPERIMENTAL
Intervention: IV fentanyl 2 mcg·kg(‐1)
Number of subjects: 90
Study 24666767 — intervention group
Group type: COMPARATOR
Intervention: Placebo (IV saline)
Number of subjects: 90
Study 22092081 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose double-blind placebo-controlled food challenge (DBPCFC) using a standardized vehicle with eight titrated protein doses from 3 μg to 1 g
Number of subjects: 0
Study 22092081 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized challenge vehicle with processed, powdered hazelnut and celeriac
Number of subjects: 0
Study 20649635 — intervention group
Group type: COMPARATOR
Intervention: Rosiglitazone (8 mg daily)
Number of subjects: 43
Study 20649635 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured physical exercise programme
Number of subjects: 43
Study 20649635 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 43
Study 18320242 — intervention group
Group type: EXPERIMENTAL
Intervention: ABM/P-15 flow
Number of subjects: 26
Study 18320242 — intervention group
Group type: COMPARATOR
Intervention: Open flap debridement
Number of subjects: 26
Study 16613261 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligustrazine (LGT)
Number of subjects: 36
Study 16613261 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (PRO)
Number of subjects: 36